In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic gives $3.75m helping hand to NanoCor:

This article was originally published in Clinica

Executive Summary

Medtronic has invested $3.75m in gene therapy start-up NanoCor Therapeutics to allow the latter to develop a treatment for congestive heart failure (CHF). NanoCor is aiming to use a genetically-engineered virus, developed using NanoCor-affiliate AskBio's Biological NanoParticle and self-complementary vector technologies, as a way of delivering drugs to failing heart muscles. If preclinical tests of the technology are successful, Medtronic has agreed to invest a further $3.75m. In return, Medtronic gains certain exclusive rights to licence the therapeutic, and rights to develop AskBio's technologies for the treatment of diseases of the central nervous system. Chapel Hill, North Carolina-based NanoCor will also use the new capital to hire six employees to join sole member of staff CEO Sheila Mikhail.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts